ArticleACS omega2025
The Vortex-Slurry Implementation: A Cheap, Easy, and Ultrafast Mechanochemical Tool to Synthesize/Screen Pharmaceutical Salts and Cocrystals.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vortex-slurry implementation is a combination of the best insights taken from multiple solid-state methods using accessible tools to improve the physical scenario, mainly designed for the supramolecular synthesis of new multicomponent pharmaceutical solid forms by coupling mechanochemistry and slurry techniques within a vortex mixer. The proposal of the vortex-slurry implementation is to provide a totally different experimental ambient capable of reaching new 3D thermodynamic states, not allowed in the current commercial mechanochemistry methods (1D mixer mill and 2D planetary mill). The obtained compounds could be easily scaled from milligrams to grams, thus opening the door for the possibility of an industrial scaling approach. The improvements achieved by this new implementation were validated by resynthesizing already reported salts and cocrystals and by presenting a new solid form for the antiviral drug Stavudine (DT4), which is an orally administered second-line drug in HIV treatment. Theoretical studies revealed that this implementation enhances the activation energy of the system due to the ball bearings' helical movements. It is expected that this implementation can spread to the scientific community, allowing manufacturability of new drug candidates and generating improvements in the quality of life of patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.